[go: up one dir, main page]

WO2002038153A1 - Nouvelle utilisation de derives de 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine - Google Patents

Nouvelle utilisation de derives de 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine Download PDF

Info

Publication number
WO2002038153A1
WO2002038153A1 PCT/SE2001/002523 SE0102523W WO0238153A1 WO 2002038153 A1 WO2002038153 A1 WO 2002038153A1 SE 0102523 W SE0102523 W SE 0102523W WO 0238153 A1 WO0238153 A1 WO 0238153A1
Authority
WO
WIPO (PCT)
Prior art keywords
imidazo
tetrahydro
rot
pyridine
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2001/002523
Other languages
English (en)
Inventor
Patrizia Caldirola
Olivier Besencon
Rolf Olsson
Johan ÖHMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0004101A external-priority patent/SE0004101D0/xx
Application filed by Biovitrum AB filed Critical Biovitrum AB
Priority to AU2002214505A priority Critical patent/AU2002214505A1/en
Publication of WO2002038153A1 publication Critical patent/WO2002038153A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to use of 4-alkyl-5-alkoxycarbonyl-4, 5, 6, 7- tetrahydroimidazo[4,5-c] pyridine derivatives for the manufacture of medicaments for, or treatment or prophylaxis of semicarbazide-sensitive amine oxidase (SSAO)-mediated complications.
  • SSAO semicarbazide-sensitive amine oxidase
  • SSAO Semicarbazide-sensitive amine oxidase
  • IDDM insulin dependent diabetes mellitus
  • NIDDM non-insulin dependent diabetes mellitus
  • Heart attack, angina, strokes, amputations, blindness and renal failure are clinical events that represent the end point of the clinical study. Endothelial cells dysfunction may precede the diabetic state of complications.
  • the SSAO enzyme is located in the vascular smooth muscles, retina, kidney and the cartilage tissues, and in the circulating blood (Yu, P. H.
  • the general catalytic cycle is very similar to the one observed for other monoamine oxidases (Scheme 1).
  • the higher activity of SSAO as well as the higher concentration of its natural substrates, methylamine and aminoacetone, in diabetic patients, would lead to a higher production of formaldehyde, methylglyoxal and hydrogen peroxide.
  • These products are known to be highly cytotoxic for the endothelial cell layer and might lead to the observed microvascular complication in diabetic patients (Yu, P. H.
  • Scheme 1 SSAO's catalytic cycle.
  • the active site is represented schematically by the topaquinone residue as well as by a basic amino acid residue B " essential for the activity.
  • a method of treatment or prophylaxis of SSAO- mediated complications in mammals including humans comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of Formula (I):
  • R 5 is (a) H
  • C j .g alkyl denotes a saturated or unsaturated, straight, branched or cyclic alkyl group having from 1 to 8 carbon atoms.
  • Examples of said Cj.g alkyl include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, and straight- and branched-chain pentyl, hexyl, septyl and octyl, optionally substituted with 0-5 halogen atoms.
  • halogen shall mean fluorine, chlorine, or bromine.
  • Preferred compound of Formula (I) are: benzyl 4-methyl-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate; benzyl 4-ethyl-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate; benzyl 4-propyl-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate;
  • the compounds of the Formula (I) can form acid addition salts with acids such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulfonic .
  • acids such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulfonic .
  • Compounds of Formula (I) may also form solvates such as hydrates and the invention also extends to these forms. When referred to herein, it is understood that the term "compound of Formula (I)" also includes these forms.
  • Certain compounds of Formula (I) are capable of existing in stereoisomeric forms including diastereomers and enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates.
  • the different stereoisomeric forms may be separated one from the other by the usual methods. Any given isomer may be obtained by stereospecific or asymmetric synthesis.
  • the invention also extends to any tautomeric forms and mixtures thereof.
  • the compounds of Formula (I) are used for treatment or prophylaxis of SSAO mediated vascular complications and for insulin dependent diabetes mellitus and non-insulin dependent diabetes mellitus.
  • R H: Benzyl (4S,6S)-6-(aminocarbonyl)-4-et yl-
  • the starting materials are commercially available or can be prepared following known procedures.
  • the compounds for treatment of SSAO mediated complications can conveniently be administered in a pharmaceutical composition containing the compound in combination with a suitable excipient.
  • Such pharmaceutical compositions can be prepared by methods and contain excipients which are well known in the art. A generally recognized compendium of such methods and ingredients is Remington's Pharmaceutical Sciences by E.W. Martin (Mark Publ. Co., 15 th Ed., 1975).
  • the compounds and compositions can be administered orally, parenterally (for example, by intravenous, intraperitoneal or intramuscular injection), topically, or rectally.
  • Useful dosages of the compounds of Formula (I) can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known in the art; for example, see U.S. Pat. No. 4,938,949.
  • the compound can be administered in unit dosage form; for example, containing about 0.05 mg to about 500 mg, conveniently about 0.1 mg to about 250 mg, most conveniently, about 1 mg to about 150 mg of active ingredient per unit dosage form.
  • the desired dose may be presented in a single dose or as divided doses administered at appropriate intervals.
  • the compositions can be administered orally, sublingually, transdermally, or parenterally at dose levels of about 0.01 to about 150 mg kg, preferably about 0.1 to about 50 mg/kg, and more preferably about 0.1 to about 30 mg/kg of mammal body weight.
  • RP-HPLCs were run on a Gilson system, using a 119 UV-detector (214 nm or 254 nm), a 805 manometric module, a 305- and a 306-pumps and a Vydac C ⁇ 8 -column (218TP1022); H 2 O+0.1%TFA/CH 3 CN were used as eluents. Mps were measured with a Gallenkamp apparatus and were uncorrected. NMR spectra were recorded on a Varian Inova 400 instrument.
  • EI-MS spectra were recorded on a JMS SX-102A mass spectrometer (Jeol, Tokyo, Jpn) at 70eV or on an Autospec-oaTOF Micromass Manchester instrument at 70 eV.
  • HRMS spectra were recorded on a LCT Micromass instrument with flow injection-electrospray positive mode; quaternary ammonium salts were used as references. Reactions were followed by MS, using a Platform I Micromass instrument, Manchester, with an electrospray positive and negative mode flow injection. Elemental analysis was run on an Elementar Vario EL instrument.
  • Benzyl chloroformate (0.845 mL, 5.64 mmol) was added dropwise over 1 min. The pH was maintained between 7 and 9 by adding from time to time aq. IM NaOH (total amount: about 5 mL). The mixture was stirred overnight while the temperature rose slowly to room temperature. The final pH was equal to 6.5 and an oily precipitate was lying in the bottom of the flask. This oily precipitate was decanted, dissolved in CHC1 3 and the solution dried over MgSO . After filtration, the filtrate was evaporated under reduced pressure. The residue was diluted in MeOH (20 mL) and aq. IM NaOH was added (10 mL).
  • Example 6 Methyl 4-methyl-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate: According to GPII, starting from 4-methyl-4,5,6,7-tetrahydro-lH- imidazo[4,5-c]pyridine dihydrochloride (500 mg, 2.38 mmol), K 2 CO 3 (690 mg, 5.00 mmol), CHC1 3 (6 mL), H 2 O (3 mL) and methyl chloroformate (0.39 mL, 5.0 mmol). The reaction was carried out in a parallel fashion in a test-tube closed with a screwed tap and stirred in a Stew-stirrer.
  • Example 7 Benzyl 4-ethyl-l ,4,6,7-tetrahydro-5H-imidazo [4,5-c]pyridine-5-carboxylate trifluoroacetate: According to GPII, starting from 4-ethyl-4,5,6,7-tetrahydro-lH- imidazo[4,5-c]pyridine dihydrochloride (1.00 g, 4.48 mmol), K 2 CO 3 (1.24 g, 9.0 mmol), CHC1 3 (10 mL), H 2 O (8 mL) and benzyl chloroformate (1.36 mL, 9.0 mmol). After basic treatment for 1 h the mixture was acidified to pH 8-8.5 with aq. IM HCl.
  • Benzyl 4-phenyI-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate trifluoroacetate According to GPII, starting from 4-phenyl-4,5,6,7- tetrahydro-lH-imidazo[4,5-c]pyridine dihydrochloride (800 mg, 2.54 mmol), K 2 CO 3 (737 mg, 5.33 mmol), CHC1 3 (6 mL), H 2 O (5 mL) and benzyl chloroformate (0.80 mL, 5.33 mmol). After basic treatment for 1 h the mixture was acidified to pH 8 with aq. IM HCl.
  • Example 9 Benzyl 4-benzyl-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate: According to GPII, starting from 4-benzyl-4,5,6,7-tetrahydro-lH-imidazo[4,5- yridine dihydrochloride (500 mg, 1.74 mmol), K 2 CO 3 (507 mg, 3.67 mmol), CHC1 3 (6 mL), H 2 O (3 mL) and benzyl chloroformate (0.55 mL, 3.67 mmol). The reaction was carried out in a parallel fashion in a test-tube closed with a screwed tap and stirred in a Stew-stirrer.
  • Benzyl 4-propyl-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate trifluoroacetate According to GPII, starting from 4-propyl-4,5,6,7- tetrahydro-lH-imidazo[4,5-c]pyridine dihydrochloride (600 mg, 2.52 mmol), K 2 CO 3 (720 mg, 5.2 mmol), CHC1 3 (6 mL), H 2 O (5 mL) and benzyl chloroformate (0.78 mL, 5.2 mmol). After basic treatment for lh the mixture was acidified to pH 8.5 with aq. IM HCl.
  • Methyl 4-ethyl-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate According to GPII, starting from 4-ethyl-4,5,6,7-tetrahydro-lH- imidazo[4,5-c]pyridine dihydrochloride (600 mg, 2.68 mmol), K 2 CO 3 (778 mg, 5.63 mmol), CHC1 3 (6 mL), H 2 O (4 mL) and methyl chloroformate (0.436 mL, 5.63 mmol). After basic treatment for 1 h the mixture was acidified to pH 8 with aq. IM HCl.
  • Methyl 4-propyl-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate trifluoroacetate According to GPII, starting from 4-propyl-4,5,6,7- tetrahydro-lH-imidazo[4,5-c]pyridine dihydrochloride (600 mg, 2.52 mmol), K 2 CO 3 (720 mg, 5.2 mmol), CHC1 3 (6 mL), H 2 O (4 mL) and methyl chloroformate (0.40 mL, 5.2 mmol). After basic treatment for 1 h the mixture was acidified to pH 8-9 with aq. IM HCl.
  • Methyl 4-phenyl-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate trifluoroacetate According to GPII, starting from 4-phenyl-4,5,6,7- tetrahydro-lH-imidazo[4,5-c] pyridine dihydrochloride (800 mg, 2.54 mmol), K 2 CO 3 (737 mg, 5.33 mmol), CHC1 3 (8 mL), H 2 O (5 mL) and methyl chloroformate (0.412 mL, 5.33 mmol). After basic treatment for 1 h the mixture was acidified to pH 8 with aq. IM HCl.
  • Cyclopentyl 4-ethyl-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridme-5- carboxylate trifluoroacetate According to GPII, starting from 4-ethyl-4,5,6,7- tetrahydro-lH-imidazo[4,5-c]pyridine dihydrochloride (400 mg, 1.78 mmol), K 2 CO 3 (517 mg, 3.74 mmol), CHC1 3 (4 mL), H 2 O (2 mL) and cyclopentyl chloroformate (511 mg, 3.74 mmol). After basic treatment for 1 h the mixture was acidified to pH 9 with aq. IM HCl.
  • Example 18 Cyclopentyl 4-propyl-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate trifluoroacetate: According to GPII, starting from 4-propyl-4,5,6,7- tetrahydro-lH-imidazo[4,5-c]pyridine dihydrochloride (400 mg, 1.68 mmol), K 2 CO 3 (487 mg, 3.53 mmol), CHC1 3 (4 mL), H 2 O (2 mL) and cyclopentyl chloroformate (482 mg, 3.53 mmol). After basic treatment for 1 h the mixture was acidified to pH 8-9 with aq. IM HCl.
  • Cyclopentyl 4-phenyl-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate trifluoroacetate According to GPII, starting from 4-phenyl-4,5,6,7- tetrahydro-lH-imidazo[4,5-c]pyridine dihydrochloride (500 mg, 1.59 mmol), K 2 CO 3 (461 mg, 3.34 mmol), CHC1 3 (5 mL), H 2 O (2.5 mL) and cyclopentyl chloroformate (456 mg, 3.34 mmol). After basic treatment for 1 h the mixture was acidified to pH 8-9 with aq. IM HCl.
  • Example 21 4-Fluorophenyl 4-propyl-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate trifluoroacetate: According to GPII, starting from 4-propyl-4,5,6,7- tetrahydro-lH-imidazo[4,5-c]pyridine dihydrochloride (400 mg, 1.68 mmol), K 2 CO 3 (487 mg, 3.53 mmol), CHC1 3 (4 mL), H 2 O (2 mL) and 4-fluorophenyl chloroformate (0.47 mg, 3.6 mmol).
  • Methoxy-ethyI 4-ethyl-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate: According to GPII, starting from 4-ethyl-4,5,6,7-tetrahydro-lH- imidazo[4,5-c]pyridine dihydrochloride (400 mg, 1.78 mmol), K CO 3 (517 mg, 3.74 mmol), CHC1 3 (4 mL), H 2 O (2 mL) and methoxyethyl chloroformate (518 mg, 3.74 mmol). After basic treatment for 1 h the mixture was acidified to pH 9 with aq. IM HCl.
  • Methoxyethyl 4-propyl-l ,4,6,7-tetrahydro-5H-imidazo [4,5-c]pyridine-5- carboxylate According to GPII, starting from 4-propyl-4,5,6,7-tetrahydro-lH- imidazo[4,5-c]pyridine dihydrochloride (400 mg, 1.68 mmol), K 2 CO 3 (487 mg, 3.53 mmol), CHC1 3 (4 mL), H 2 O (2 mL) and methoxyethyl chloroformate (490 mg, 3.53 mmol). After basic treatment for 1 h the mixture was acidified to pH 8-9 with aq. IM HCl.
  • Methoxyethyl 4-phenyl-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate According to GPII, starting from 4-phenyl-4,5,6,7-tetrahydro-lH- imidazo[4,5-c]pyridine dihydrochloride (500 mg, 1.59 mmol), K 2 CO 3 (461 mg, 3.34 mmol), CHC1 3 (6 mL), H 2 O (4 mL) and methoxyethyl chloroformate (462 mg, 3.34 mmol). After basic treatment for 1 h the mixture was acidified to pH 8-9 with aq. IM HCl.
  • Benzyl 4-methyl-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate According to GPII, starting from 4-methyl-4,5,6,7-tetrahydro-lH- imidazo[4,5-c]pyridine dihydrochloride (500 mg, 2.38 mmol), K 2 CO 3 (690 mg, 5.00 mmol), CHC1 3 (6 mL), H 2 O (3 mL) and benzyl chloroformate (0.75 mL, 5.0 mmol). The reaction was carried out in a parallel fashion in a test-tube closed with a screwed tap and stirred in a Ste -stirrer.
  • Benzyl 4-benzyl-l ,4,6,7-tetrahydro-5H-imidazo [4,5-c]pyridine-5- carboxylate According to GPII, starting from 4-benzyl-4,5,6,7-tetrahydro-lH- imidazo[4,5-c]pyridine dihydrochloride (500 mg, 1.74 mmol), K 2 CO 3 (507 mg, 3.67 mmol), CHC1 3 (6 mL), H 2 O (3 mL) and benzyl chloroformate (0.55 mL, 3.67 mmol). The reaction was carried out in a parallel fashion in a test-tube closed with a screwed tap and stirred in a Ste ⁇ n-stirrer.
  • the reaction was carried out in a parallel fashion in a test-tube closed with a screwed tap and stirred in a Stem-stirrer.
  • the basic treatment was carried out in MeOH (6 mL) and aq. IM NaOH (4 mL). After 1 h the mixture was acidified with aq. IM HCl (3 mL). The reaction mixture was evaporated in a speed-vac overnight. The residue was triturated with CHC1 3 and filtered several times. The combined org. phases were evaporated in a speed- vac.
  • the residue was purified by parallel FC with a gradient pump (MeOH/CHCl 3 0:100 -> 0:100 for 5 min, then -> 15:85 over 25 min).
  • 5-carboxylate According to GPII, starting from 4-ethyl-4,5,6,7-tetrahydro-lH- imidazo[4,5-c]pyridine dihydrochloride (500 mg, 2.23 mmol), K 2 CO 3 (646 mg, 4.68 mmol), CHC1 3 (6 mL), H 2 O (3 mL) and 2,2,2-trichloroethyl chloroformate (0.64 mL, 4.68 mmol). The reaction was carried out in a parallel fashion in a test-tube closed with a screwed tap and stirred in a Stem-stirrer. The basic treatment was carried out in MeOH (6 mL) and aq. IM NaOH (4 mL).
  • 2,2,2-Trichloroethyl -4-propy 1-1 ,4,6,7-tetrahy dro-5H-imidazo [4,5- c]pyridine-5-carboxylate According to GPII, starting from 4-propyl-4,5,6,7- tetrahydro-lH-imidazo[4,5-c]pyridine dihydrochloride (500 mg, 2.10 mmol), K 2 CO 3 (609 mg, 4.40 mmol), CHC1 3 (6 mL), H 2 O (3 mL) and 2,2,2-trichloroethyl chloroformate (0.61 mL, 4.4 mmol).
  • the reaction was carried out in a parallel fashion in a test-tube closed with a screwed tap and stirred in a Stew-stirrer.
  • the basic treatment was carried out in MeOH (6 mL) and aq. IM NaOH (4 mL). After 1 h the mixture was acidified with aq. IM HCl (3 mL). The reaction mixture was evaporated in a speed-vac overnight. The residue was triturated with CHC1 3 and filtered several times. The combined org. phases were evaporated in a speed-vac.
  • the residue was purified by parallel FC with a gradient pump (MeOH/CHCl 3 0:100 ⁇ 0:100 for 5 min, then ⁇ 15:85 over 25 min).
  • 2,2,2-Trichloroethyl -4-propyl-l ,4,6,7-tetrahydro-5H-imidazo [4,5- c]pyridine-5-carboxylate According to GPII, starting from 4-propyl-4,5,6,7- tetrahydro-lH-imidazo[4,5-c]pyridine dihydrochloride (500 mg, 2.10 mmol), K 2 CO 3 (609 mg, 4.40 mmol), CHC1 3 (6 mL), H 2 O (3 mL) and 2,2,2-trichloroethyl chloroformate (0.61 mL, 4.4 mmol).
  • the reaction was carried out in a parallel fashion in a test-tube closed with a screwed tap and stirred in a Stem-stirrer.
  • the basic treatment was carried out in MeOH (6 mL) and aq. IM NaOH (4 mL). After 1 h the mixture was acidified with aq. IM HCl (3 mL). The reaction mixture was evaporated in a speed- vac overnight. The residue was triturated with CHC1 3 and filtered several times. The combined org. phases were evaporated in a speed-vac.
  • the residue was purified by parallel FC with a gradient pump (MeOH/CHCl 3 0:100 ⁇ 0:100 for 5 min, then ⁇ 15:85 over 25 min).
  • the reaction was carried out in a parallel fashion in a test-tube closed with a screwed tap and stirred in a Stem-stirrer.
  • the basic treatment was carried out in MeOH (6 mL) and aq. IM NaOH (4 mL). After 1 h the mixture was acidified with aq. IM HCl (3 mL). The reaction mixture was evaporated in a speed-vac overnight. The residue was triturated with CHC1 3 and filtered several times. The combined org. phases were evaporated in a speed- vac.
  • Example 37 o 5-(4-Nitrob enzyl)-4-propyl-l ,4,6,7-tetrahy dro-5H-imidazo [4,5-c] py ridine-5- carboxylate: According to GPII, starting from 4-propyl-4,5,6,7-tetrahydro-lH- imidazo[4,5-c]pyridine dihydrochloride (500 mg, 2.10 mmol), K 2 CO 3 (609 mg, 4.40 mmol), CHC1 3 (6 mL), H 2 O (3 mL) and old 4-nitrophenyl chloroformate (949 mg, 4.40 mmol).
  • This method is based on the horseradish peroxidase catalyzed hydrogen peroxide oxidation of 10-acetyl-3,7-dihydroxyphenoxazine (Molecular Probes A-6550), that yields a highly fluorescent product, resorufin.
  • 10 mM stock solution of substance in DMSO is serially diluted in 0.05 M sodium-potassium phosphate buffer.
  • SSAO substrate benzylamine
  • HRP horse radish peroxidase
  • the final concentrations in the assay volume are 104 ⁇ M benzylamine, 219 ⁇ M 10-acetyl-3,7-dihydroxyphenoxazine, 1.1 U/ml HRP and a dilution of the SSAO preparation of 1/600.
  • the fluorescence is measured at 560 ex / 590 em.
  • the inhibition is measured as % decrease of the signal compared to a control containing dilution of DMSO only (no substance).
  • Aldehyde detection SSAO activity is measured as increase of aldehyde formed from SSAO degradation of primary amines.
  • 14 C -labeled benzylamine is mixed with substance dilutions (from 10 mM stock solution in DMSO) in 0.05 M sodium-potassium phosphate buffer (pH 7.8). Enzyme, also diluted in phosphate buffer, is added and incubation is performed at room temperature for 60 minutes. The reaction is stopped with 1 M HCl. The formed ( 1 C -labeled) aldehyde is separated from the likewise 14 C -labeled benzylamine through extraction with toluene:ethyl acetate and then transferred to liquid scintillation vials for measurement of radioactivity in a beta counter.
  • the final concentrations in the assay volume are 150 ⁇ M benzylamine (0.037 MBq/ ⁇ mol), and a dilution of the SSAO preparation of l/150.
  • the inhibition is measured as % decrease of the signal compared to control containing dilution of DMSO only (no substance).
  • the compounds shown in Tables 2 and 3 were tested for biological activity, determined as per cent inhibition of SSAO at 12 ⁇ M concentration of the test compounds. The compounds were shown to inhibit SSAO to from 10 to 97 %.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne l'utilisation de composés représentés par la formule (I), dans laquelle R?1, R2, R3 et R4¿ sont tels que spécifiés dans la description, pour le traitement ou la prévention de complications à médiation de SSAO, telles que le diabète.
PCT/SE2001/002523 2000-11-09 2001-11-09 Nouvelle utilisation de derives de 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine Ceased WO2002038153A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002214505A AU2002214505A1 (en) 2000-11-09 2001-11-09 New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0004101A SE0004101D0 (sv) 2000-11-09 2000-11-09 New use
SE0004101-2 2000-11-09
US25215600P 2000-11-20 2000-11-20
US60/252,156 2000-11-20

Publications (1)

Publication Number Publication Date
WO2002038153A1 true WO2002038153A1 (fr) 2002-05-16

Family

ID=26655299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2001/002523 Ceased WO2002038153A1 (fr) 2000-11-09 2001-11-09 Nouvelle utilisation de derives de 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine

Country Status (2)

Country Link
AU (1) AU2002214505A1 (fr)
WO (1) WO2002038153A1 (fr)

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051842A3 (fr) * 2001-12-14 2004-06-03 Novo Nordisk As Utilisation de composes pour reduire l'activite de la lipase hormono-sensible
WO2005063261A1 (fr) * 2003-12-31 2005-07-14 Faron Pharmaceuticals Oy Antibiotiques aminoglycosides utilises comme inhibiteurs de la vap-1/ssao
WO2005072738A1 (fr) * 2004-01-30 2005-08-11 Faron Pharmaceuticals Oy Compositions particulierement utiles au traitement ou a la prevention du syndrome metabolique
US7071355B2 (en) 2002-12-23 2006-07-04 4 Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7125901B2 (en) 2003-01-27 2006-10-24 Astellas Pharma Inc. Thiazole derivatives
US7247736B2 (en) 2002-12-23 2007-07-24 4Sc Ag Method of identifying inhibitors of DHODH
JP2008508188A (ja) * 2004-07-27 2008-03-21 アステラス製薬株式会社 Ｖａｐ−１阻害剤活性を有するチアゾール誘導体
US7365094B2 (en) 2002-12-23 2008-04-29 4Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2010031791A1 (fr) * 2008-09-16 2010-03-25 Biovitrum Ab (Publ) Composés inédits ii
WO2010031789A1 (fr) * 2008-09-16 2010-03-25 Biovitrum Ab (Publ) Composés inédits i
WO2010064020A1 (fr) 2008-12-04 2010-06-10 Proximagen Ltd. Composés imidazopyridines
EP2283833A2 (fr) 2004-02-25 2011-02-16 La Jolla Pharmaceutical Co. Amines et amides pour le traitement de maladies
KR20110022574A (ko) 2008-05-30 2011-03-07 가부시키가이샤 아루떼꾸 우에노 벤젠 또는 티오펜 유도체 및 ｖａｐ－１ 억제제로서 이의 용도
WO2011029996A1 (fr) 2009-09-08 2011-03-17 Biotie Therapies Corp. Utilisation d'inhibiteurs de vap-1 pour traiter des lésions fibreuses
WO2011034078A1 (fr) 2009-09-16 2011-03-24 アステラス製薬株式会社 Composé de glycine
WO2011113798A2 (fr) 2010-03-15 2011-09-22 Proximagen Limited Nouveaux composés d'inhibiteurs enzymatiques
US8119651B2 (en) 2004-01-30 2012-02-21 Biotie Therapies Corp. Compositions useful especially for treatment or prevention of metabolic syndrome
WO2012120195A1 (fr) 2011-03-08 2012-09-13 Biotie Therapies Corporation Nouveaux composés de pyridazinone et pyridone
WO2012124696A1 (fr) 2011-03-15 2012-09-20 アステラス製薬株式会社 Composé de guanidine
WO2013038189A1 (fr) 2011-09-14 2013-03-21 Proximagen Ltd. Nouveaux composés inhibiteurs d'enzymes
WO2013037411A1 (fr) 2011-09-14 2013-03-21 Proximagen Limited Nouveaux composés inhibiteurs enzymatiques
US8507690B2 (en) 2008-01-31 2013-08-13 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as VAP-1 inhibitor
US20140275013A1 (en) * 2013-03-15 2014-09-18 University Of Washington Through Its Center For Commercialization Compounds and compositions for the treatment of parasitic diseases
WO2014199171A1 (fr) 2013-06-12 2014-12-18 Proximagen Limited Nouvelles utilisations thérapeutiques d'inhibiteurs enzymatiques
WO2015159112A1 (fr) 2014-04-15 2015-10-22 Pécsi Tudományegyetem Inhibiteurs d'amine oxydase sensibles au semi-carbazide, destinés à être utilisés comme analgésiques dans une neuropathie traumatique et une inflammation neurogène
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2015189534A1 (fr) 2014-06-12 2015-12-17 Proximagen Limited Inhibiteurs de vap-1 pour le traitement de la dystrophie musculaire
WO2016042332A1 (fr) * 2014-09-17 2016-03-24 Proximagen Limited Inhibiteurs d'une ssao dérivés d'une imidazo[4,5-c]pyridine
WO2016042331A1 (fr) * 2014-09-17 2016-03-24 Proximagen Limited Inhibiteur de ssao dérivé d'imidazo[4,5-c]pyridine
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9303034B2 (en) 2013-12-19 2016-04-05 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9428498B2 (en) 2013-03-13 2016-08-30 Proximagen Limited Substituted imidazo[4,5-c]pyridine compounds and compositions thereof
WO2016194390A1 (fr) 2015-06-05 2016-12-08 R-Tech Ueno, Ltd. Composition pharmaceutique pour utilisation dans le traitement du cancer
US9580415B2 (en) 2013-03-13 2017-02-28 Proximagen Limited Compounds
US9765092B2 (en) 2013-11-19 2017-09-19 Actelion Pharmaceuticals Ltd Tricyclic piperidine compounds
CN107915719A (zh) * 2017-12-29 2018-04-17 佛山汉方中医医院有限公司 一类甲基金刚烷和吡啶结构的ssao抑制剂及其用途
CN107935989A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 金刚烷和腈基吡啶结构化合物、其制备方法及用途
CN107935993A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 甲基金刚烷和硝基吡啶结构衍生物、其制备方法及其用途
CN107935992A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 一类含金刚烷和卤代吡啶结构化合物及用途
CN107935990A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 含金刚烷和烷氧吡啶结构化合物、其制备方法及用途
CN108033945A (zh) * 2017-12-29 2018-05-15 佛山汉方中医医院有限公司 一种金刚烷和硝基吡啶结构化合物及用途
CN108033946A (zh) * 2017-12-29 2018-05-15 佛山汉方中医医院有限公司 一种含金刚烷结构的ssao抑制剂、制备方法及其用途
JP2018513189A (ja) * 2015-04-24 2018-05-24 プロキシマジェン リミティド セミカルバジド感受性アミンオキシダーゼ（ｓｓａｏ）の阻害剤の医薬的塩形態
CN108084155A (zh) * 2017-12-29 2018-05-29 佛山汉方中医医院有限公司 甲基金刚烷和烷氧吡啶结构的ssao抑制剂及其用途
CN108084154A (zh) * 2017-12-29 2018-05-29 佛山汉方中医医院有限公司 一种金刚烷和胺基吡啶结构衍生物、其制备方法及用途
CN108129458A (zh) * 2017-12-29 2018-06-08 佛山汉方中医医院有限公司 一种金刚烷和二甲胺吡啶结构衍生物、其制备方法及用途
CN108191825A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一种甲基金刚烷和硝基吡啶结构衍生物及其用途
CN108191823A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一类烷基取代金刚烷ssao抑制剂、制备方法及其用途
CN108191824A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一种甲基金刚烷和二甲胺吡啶结构衍生物、其制备方法及其用途
JP2018517683A (ja) * 2015-05-04 2018-07-05 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ 三環式ピペリジン化合物
JP2018524392A (ja) * 2015-07-24 2018-08-30 ベネボレンタイ ケンブリッジ リミティド 新規治療用化合物及びその治療における使用
US10189839B2 (en) 2013-11-19 2019-01-29 Actelion Pharmaceuticals Ltd Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase
CN109988147A (zh) * 2017-12-29 2019-07-09 佛山汉方中医医院有限公司 含金刚烷结构的ssao抑制剂、制备方法及其用途
US10369139B2 (en) 2015-04-24 2019-08-06 Benevolentai Cambridge Limited Crystalline compound as semicarbazide-sensitive amine oxidase (SSAO) enzyme inhibitor
EP3777846A1 (fr) 2015-12-07 2021-02-17 BenevolentAI Cambridge Limited Inhibiteurs de vap-1 for traitmanet de la douleur

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141899A (en) * 1976-01-07 1979-02-27 Societa' Farmaceutici Italia S.P.A. 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives
GB2158440A (en) * 1985-01-22 1985-11-13 Erba Farmitalia 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine derivatives
WO1993023023A1 (fr) * 1992-05-15 1993-11-25 University Of Saskatchewan Procede pour prevenir les lesions de l'endothelium chez les mammiferes et pour soulager la douleur provoquee par la goutte et l'arthrite
WO2000063208A1 (fr) * 1999-04-16 2000-10-26 Novo Nordisk A/S Imidazoles substitues, leur preparation et utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141899A (en) * 1976-01-07 1979-02-27 Societa' Farmaceutici Italia S.P.A. 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives
GB2158440A (en) * 1985-01-22 1985-11-13 Erba Farmitalia 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine derivatives
WO1993023023A1 (fr) * 1992-05-15 1993-11-25 University Of Saskatchewan Procede pour prevenir les lesions de l'endothelium chez les mammiferes et pour soulager la douleur provoquee par la goutte et l'arthrite
WO2000063208A1 (fr) * 1999-04-16 2000-10-26 Novo Nordisk A/S Imidazoles substitues, leur preparation et utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANIM., PLANT MICROB. TOXINS, PROC. INT. SYMP., 4TH (1976) MEETING DATE 1974, vol. 1, 1976, pages 273 - 286 *
DATABASE CAPLUS [online] PREUSSER H.J. ET AL.: "Antimicrobial activity of alkaloids from amphibian venoms and effects on the ultrastructure of yeast cells", XP002908095, accession no. STN Database accession no. 1977:479326 *

Cited By (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067517B2 (en) 2001-12-14 2006-06-27 Nero Nordisk A/S Use of compounds for decreasing activity of hormone-sensitive lipase
WO2003051841A3 (fr) * 2001-12-14 2004-06-24 Novo Nordisk As Composes ralentissant l'activite de la lipase hormono-sensible
WO2003051842A3 (fr) * 2001-12-14 2004-06-03 Novo Nordisk As Utilisation de composes pour reduire l'activite de la lipase hormono-sensible
US7279470B2 (en) 2001-12-14 2007-10-09 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
US7365094B2 (en) 2002-12-23 2008-04-29 4Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7247736B2 (en) 2002-12-23 2007-07-24 4Sc Ag Method of identifying inhibitors of DHODH
US7071355B2 (en) 2002-12-23 2006-07-04 4 Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7442715B2 (en) 2003-01-27 2008-10-28 Astellas Pharma Inc. Thiazole derivatives
US7125901B2 (en) 2003-01-27 2006-10-24 Astellas Pharma Inc. Thiazole derivatives
WO2005063261A1 (fr) * 2003-12-31 2005-07-14 Faron Pharmaceuticals Oy Antibiotiques aminoglycosides utilises comme inhibiteurs de la vap-1/ssao
WO2005072738A1 (fr) * 2004-01-30 2005-08-11 Faron Pharmaceuticals Oy Compositions particulierement utiles au traitement ou a la prevention du syndrome metabolique
US8119651B2 (en) 2004-01-30 2012-02-21 Biotie Therapies Corp. Compositions useful especially for treatment or prevention of metabolic syndrome
EP2283833A2 (fr) 2004-02-25 2011-02-16 La Jolla Pharmaceutical Co. Amines et amides pour le traitement de maladies
JP2008508188A (ja) * 2004-07-27 2008-03-21 アステラス製薬株式会社 Ｖａｐ−１阻害剤活性を有するチアゾール誘導体
EP2676955A1 (fr) 2008-01-31 2013-12-25 R-Tech Ueno, Ltd. Dérivé de thiazole et son utilisation en tant qu'inhibiteur VAP-1
US8507690B2 (en) 2008-01-31 2013-08-13 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as VAP-1 inhibitor
EP2886534A1 (fr) 2008-05-30 2015-06-24 R-Tech Ueno, Ltd. Dérivé de benzène ou thiophène et son utilisation en tant qu'inhibiteur VAP-1
US8999989B2 (en) 2008-05-30 2015-04-07 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
KR20110022574A (ko) 2008-05-30 2011-03-07 가부시키가이샤 아루떼꾸 우에노 벤젠 또는 티오펜 유도체 및 ｖａｐ－１ 억제제로서 이의 용도
US9603833B2 (en) 2008-05-30 2017-03-28 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
JP2012506368A (ja) * 2008-09-16 2012-03-15 プロキシマジェン エルティーディー 新規化合物ｉ
EA019167B1 (ru) * 2008-09-16 2014-01-30 Проксимаген Лимитед Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
WO2010031791A1 (fr) * 2008-09-16 2010-03-25 Biovitrum Ab (Publ) Composés inédits ii
US8263616B2 (en) 2008-09-16 2012-09-11 Proximagen Ltd 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds
WO2010031789A1 (fr) * 2008-09-16 2010-03-25 Biovitrum Ab (Publ) Composés inédits i
US11040969B2 (en) 2008-09-16 2021-06-22 Benevolentai Cambridge Limited Compounds I
US9035066B2 (en) 2008-09-16 2015-05-19 Proximagen Limited Method of using 4,5,6,7-tetrahydroimidazo[4,5-C]pyridine compounds
US10399973B2 (en) 2008-09-16 2019-09-03 Benevolentai Cambridge Limited Compounds I
US20110195992A1 (en) * 2008-09-16 2011-08-11 Proximagen Limited New compounds ii
US8569338B2 (en) 2008-09-16 2013-10-29 Proximagen Ltd. Methods of using 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine compounds
AU2009294660B2 (en) * 2008-09-16 2013-11-14 Benevolentai Cambridge Limited New compounds I
US9493457B2 (en) 2008-09-16 2016-11-15 Proximagen Limited 4,5,6,7-tetrahyroimidazo[4,5-c]pyridine compounds
US8633318B2 (en) 2008-09-16 2014-01-21 Proximagen Ltd Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder
US9890160B2 (en) 2008-09-16 2018-02-13 Proximagen Limited Compounds I
WO2010064020A1 (fr) 2008-12-04 2010-06-10 Proximagen Ltd. Composés imidazopyridines
US9795671B2 (en) 2009-09-08 2017-10-24 Biotie Therapies Corp. Use of VAP-1 inhibitors for treating fibrotic conditions
WO2011029996A1 (fr) 2009-09-08 2011-03-17 Biotie Therapies Corp. Utilisation d'inhibiteurs de vap-1 pour traiter des lésions fibreuses
RU2580626C2 (ru) * 2009-09-08 2016-04-10 Байотай Терапис Корп. Применение ингибиторов vap-1 для лечения фиброзных болезней
US10576148B2 (en) 2009-09-08 2020-03-03 Biotie Therapies Corp. Use of VAP-1 inhibitors for treating fibrotic conditions
US8802679B2 (en) 2009-09-16 2014-08-12 Astellas Pharma Inc. Glycine compound
WO2011034078A1 (fr) 2009-09-16 2011-03-24 アステラス製薬株式会社 Composé de glycine
WO2011113798A2 (fr) 2010-03-15 2011-09-22 Proximagen Limited Nouveaux composés d'inhibiteurs enzymatiques
EP2927233A1 (fr) 2010-03-15 2015-10-07 Proximagen Limited Inhibiteurs de amine oxydase sensible à semicarbazide
US9227967B2 (en) 2010-03-15 2016-01-05 Proximagen Limited Inhibitor compounds of semicarbazide-sensitive amine oxidases
WO2012120195A1 (fr) 2011-03-08 2012-09-13 Biotie Therapies Corporation Nouveaux composés de pyridazinone et pyridone
EP3002278A1 (fr) 2011-03-15 2016-04-06 Astellas Pharma Inc. Composé de guanidine
US9051283B2 (en) 2011-03-15 2015-06-09 Astellas Pharma Inc. Guanidine compound
KR20140014153A (ko) 2011-03-15 2014-02-05 아스테라스 세이야쿠 가부시키가이샤 구아니딘 화합물
US8716470B2 (en) 2011-03-15 2014-05-06 Astellas Pharma Inc. Guanidine compound
US9556160B2 (en) 2011-03-15 2017-01-31 Astellas Pharma Inc. Guanidine compound
WO2012124696A1 (fr) 2011-03-15 2012-09-20 アステラス製薬株式会社 Composé de guanidine
WO2013037411A1 (fr) 2011-09-14 2013-03-21 Proximagen Limited Nouveaux composés inhibiteurs enzymatiques
CN103889983B (zh) * 2011-09-14 2015-12-09 普罗克西梅根有限公司 酶抑制剂化合物
WO2013038189A1 (fr) 2011-09-14 2013-03-21 Proximagen Ltd. Nouveaux composés inhibiteurs d'enzymes
US9150574B2 (en) 2011-09-14 2015-10-06 Proximagen Limited Enzyme inhibitor compounds
CN103889983A (zh) * 2011-09-14 2014-06-25 普罗克西梅根有限公司 新型酶抑制剂化合物
US9580415B2 (en) 2013-03-13 2017-02-28 Proximagen Limited Compounds
US10968223B2 (en) 2013-03-13 2021-04-06 Proximagen, Llc Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors
US9428498B2 (en) 2013-03-13 2016-08-30 Proximagen Limited Substituted imidazo[4,5-c]pyridine compounds and compositions thereof
US9951068B2 (en) 2013-03-13 2018-04-24 Proximagen Limited Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors
US10428066B2 (en) 2013-03-13 2019-10-01 Proximagen, Llc Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors
US10590125B2 (en) 2013-03-13 2020-03-17 Proximagen, Llc Compounds
US11512082B2 (en) 2013-03-13 2022-11-29 Proximagen, Llc Substituted imidazo[4,5-c]pyridine compounds and compositions thereof
US10766897B2 (en) 2013-03-13 2020-09-08 Proximagen, Llc Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors
US9676769B2 (en) 2013-03-13 2017-06-13 Proximagen Limited Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US20140275013A1 (en) * 2013-03-15 2014-09-18 University Of Washington Through Its Center For Commercialization Compounds and compositions for the treatment of parasitic diseases
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2014199171A1 (fr) 2013-06-12 2014-12-18 Proximagen Limited Nouvelles utilisations thérapeutiques d'inhibiteurs enzymatiques
US9765092B2 (en) 2013-11-19 2017-09-19 Actelion Pharmaceuticals Ltd Tricyclic piperidine compounds
US10189839B2 (en) 2013-11-19 2019-01-29 Actelion Pharmaceuticals Ltd Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase
US10085989B2 (en) 2013-12-19 2018-10-02 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US10596175B2 (en) 2013-12-19 2020-03-24 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9700559B2 (en) 2013-12-19 2017-07-11 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9303034B2 (en) 2013-12-19 2016-04-05 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US11123348B2 (en) 2013-12-19 2021-09-21 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2015159112A1 (fr) 2014-04-15 2015-10-22 Pécsi Tudományegyetem Inhibiteurs d'amine oxydase sensibles au semi-carbazide, destinés à être utilisés comme analgésiques dans une neuropathie traumatique et une inflammation neurogène
WO2015189534A1 (fr) 2014-06-12 2015-12-17 Proximagen Limited Inhibiteurs de vap-1 pour le traitement de la dystrophie musculaire
AU2015316611B2 (en) * 2014-09-17 2019-05-30 Proximagen, Llc Imidazo[4,5-c]pyridine derived SSAO inhibitors
CN107074853A (zh) * 2014-09-17 2017-08-18 普罗克斯马根有限公司 咪唑并[4,5‑c]吡啶衍生的SSAO抑制剂
AU2015316610B2 (en) * 2014-09-17 2019-05-30 Proximagen, Llc Imidazo[4,5-c]pyridine derived SSAO inhibitors
US11530208B2 (en) 2014-09-17 2022-12-20 Proximagen, Llc Imidazo[4,5-C]pyridine derived SSAO inhibitors
WO2016042332A1 (fr) * 2014-09-17 2016-03-24 Proximagen Limited Inhibiteurs d'une ssao dérivés d'une imidazo[4,5-c]pyridine
WO2016042331A1 (fr) * 2014-09-17 2016-03-24 Proximagen Limited Inhibiteur de ssao dérivé d'imidazo[4,5-c]pyridine
CN107074854A (zh) * 2014-09-17 2017-08-18 普罗克斯马根有限公司 咪唑并[4，5‑c]吡啶衍生的SSAO抑制剂
CN107074854B (zh) * 2014-09-17 2019-07-19 普罗克斯马根有限责任公司 咪唑并[4，5-c]吡啶衍生的SSAO抑制剂
JP2017528493A (ja) * 2014-09-17 2017-09-28 プロクシマゲン リミテッド イミダゾ［４，５‐ｃ］ピリジン由来のｓｓａｏ阻害剤
JP2017532315A (ja) * 2014-09-17 2017-11-02 プロクシマゲン リミテッド イミダゾ［４，５‐ｃ］ピリジン由来のｓｓａｏ阻害剤
CN107074853B (zh) * 2014-09-17 2019-07-23 普罗克斯马根有限责任公司 咪唑并[4，5-c]吡啶衍生的SSAO抑制剂
US10065954B2 (en) 2014-09-17 2018-09-04 Proximagen Limited Substituted imidazo[4,5-c]pyridines as SSAO inhibitors
US10369139B2 (en) 2015-04-24 2019-08-06 Benevolentai Cambridge Limited Crystalline compound as semicarbazide-sensitive amine oxidase (SSAO) enzyme inhibitor
US10316034B2 (en) 2015-04-24 2019-06-11 Benevolentai Cambridge Limited Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (SSAO)
JP2018513189A (ja) * 2015-04-24 2018-05-24 プロキシマジェン リミティド セミカルバジド感受性アミンオキシダーゼ（ｓｓａｏ）の阻害剤の医薬的塩形態
JP2018517683A (ja) * 2015-05-04 2018-07-05 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ 三環式ピペリジン化合物
WO2016194390A1 (fr) 2015-06-05 2016-12-08 R-Tech Ueno, Ltd. Composition pharmaceutique pour utilisation dans le traitement du cancer
JP2021035977A (ja) * 2015-07-24 2021-03-04 プロキシマジェン，リミティド ライアビリティ カンパニー 新規治療用化合物及びその治療における使用
JP2018524392A (ja) * 2015-07-24 2018-08-30 ベネボレンタイ ケンブリッジ リミティド 新規治療用化合物及びその治療における使用
EP3777846A1 (fr) 2015-12-07 2021-02-17 BenevolentAI Cambridge Limited Inhibiteurs de vap-1 for traitmanet de la douleur
CN108191823A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一类烷基取代金刚烷ssao抑制剂、制备方法及其用途
CN108191824A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一种甲基金刚烷和二甲胺吡啶结构衍生物、其制备方法及其用途
CN107935989A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 金刚烷和腈基吡啶结构化合物、其制备方法及用途
CN107915719A (zh) * 2017-12-29 2018-04-17 佛山汉方中医医院有限公司 一类甲基金刚烷和吡啶结构的ssao抑制剂及其用途
CN108033946A (zh) * 2017-12-29 2018-05-15 佛山汉方中医医院有限公司 一种含金刚烷结构的ssao抑制剂、制备方法及其用途
CN107935990A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 含金刚烷和烷氧吡啶结构化合物、其制备方法及用途
CN108033945A (zh) * 2017-12-29 2018-05-15 佛山汉方中医医院有限公司 一种金刚烷和硝基吡啶结构化合物及用途
CN107935993A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 甲基金刚烷和硝基吡啶结构衍生物、其制备方法及其用途
CN107935992A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 一类含金刚烷和卤代吡啶结构化合物及用途
CN108191825A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一种甲基金刚烷和硝基吡啶结构衍生物及其用途
CN109988147A (zh) * 2017-12-29 2019-07-09 佛山汉方中医医院有限公司 含金刚烷结构的ssao抑制剂、制备方法及其用途
CN108129458A (zh) * 2017-12-29 2018-06-08 佛山汉方中医医院有限公司 一种金刚烷和二甲胺吡啶结构衍生物、其制备方法及用途
CN108084154A (zh) * 2017-12-29 2018-05-29 佛山汉方中医医院有限公司 一种金刚烷和胺基吡啶结构衍生物、其制备方法及用途
CN108084155A (zh) * 2017-12-29 2018-05-29 佛山汉方中医医院有限公司 甲基金刚烷和烷氧吡啶结构的ssao抑制剂及其用途

Also Published As

Publication number Publication date
AU2002214505A1 (en) 2002-05-21

Similar Documents

Publication Publication Date Title
WO2002038153A1 (fr) Nouvelle utilisation de derives de 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine
AU2020343671B2 (en) RIP1 inhibitory compounds and methods for making and using the same
US11459312B2 (en) Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
US6043252A (en) Carboline derivatives
ES2585262T3 (es) Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
KR101126383B1 (ko) 3환계 화합물
JP2002528533A (ja) 酵素ｉｍｐｄｈの新規なインヒビター
WO2018118947A1 (fr) Dérivés de thiénopyrrole destinés à être utilisés dans le ciblage de protéines, compositions, procédés et utilisations associés
ZA200604528B (en) Polycyclic agents for the treatment of respiratory syncytial virus infections
EA016575B1 (ru) Производные карболина, полезные в ингибировании ангиогенеза
US11524944B2 (en) 2-phenylpyrimidine-4-carboxamides as AHR inhibitors
WO2005047286A1 (fr) Compose spiranique heterocyclique
JP2000513717A (ja) カルボリン誘導体
JP2017537948A (ja) Ｎａｄｐｈオキシダーゼ阻害剤としてのアミドチアジアゾール誘導体
EA035592B1 (ru) Ингибиторы деацетилаз гистонов и композиции и способы их применения
SK20182000A3 (sk) Činidlo regulujúce funkciu receptora súvisiaceho s retinoidmi
US12152036B2 (en) Substituted pyrrolo[1,2-α]quinoxalin-4(5H)-ones as CX3CR1 antagonists
AU2013364038B2 (en) Diazole amides
TWI771303B (zh) 化合物及其於降低尿酸位準之用途(一)
JP2013532657A (ja) 環式ｎ，ｎ’−ジアリールチオ尿素及びｎ，ｎ’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
US20020198189A1 (en) New use
TW201120042A (en) N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
JP2022544199A (ja) Ａｃｃ阻害剤としてのチエノピリミジン誘導体及びその使用
KR20240172217A (ko) 암 치료를 위한 락테이트/atp 생성 억제제로서의 n-(3-(벤조[b]티오펜-2-카르복스아미도)-페닐)-2,3-디하이드로벤조[b][1,4]다이옥신-6-카르복스아미드 유도체 및 관련 화합물
EA036965B1 (ru) Ингибиторы деацетилаз гистонов и композиции и способы их применения

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP